Lisocabtagene Maraleucel (JCAR017) full coverage report- Mellalta Meets findings

 
NEW YORK - July 24, 2020 - PRLog -- Lisocabtagene maraleucel, also known as liso-cel and JCAR017 is a 4-1BB-based second generation CAR-T therapy, that contains a distinct IgG4-based hinge. The therapy is a key pipeline asset which Bristol-Myers picked up through its takeover of Celgene, originally belongs to Juno Therapeutics.

On July 17, 2020, Bristol's liso-cel was validated for MAA by EMA for Relapsed or refractory (R/R) diffuse large B-cell lymphoma, primary mediastinal B-cell lymphoma and follicular lymphoma grade 3B. The Therapy is also under review by FDA for Relapsed or refractory (R/R) large B-cell lymphoma with extended PDUFA date of 16th November 2020.

Roughly 30% to 40% of patients develop relapsed/refractory DLBCL, which, in addition to being associated with a significantly increased risk of morbidity and mortality, presents unique treatment challenges.

CAR-T Therapy: Kymriah vs Yescarta vs Liso-cel (JCAR017) on Efficacy & Safety Terms

CAR-T Therapy Vein to Vein Manufacturing Turnaround Time of Liso-cell (JCAR017)

Bristol's liso-cel CAR-T Therapy Outpatient setting

In the TRANSCEND NHL 001 (NCT02631044), PILOT (NCT03483103), and OUTREACH (NCT03744676) studies, results showed that outpatient treatment had comparable clinical outcomes and toxicity as treatment across all patients and data demonstrating the use of machine learning.

Suggested feasibility of this approach

Potentiating wider use of CAR-T Therapy in DLBCL

"Using a proprietary data integration platform, we've been able to deploy machine learning approaches to develop critical insights for our programs including optimize patient selection, rational combinations for platform studies and process improvements that have given rise to our Nex-T products that are now in the clinic. The Nex-T has the potential to markedly impact turnaround time and cost of goods for autologous cell therapy," Vessey, EVP BMS.

Outpatient monitoring involves daily clinical visits or phone calls for the first 7 days, then at least twice a week for up to 30 days

The patient should stay close to the treatment center so that they can be quickly admitted with signs of symptoms.

CAR-T Therapy JCAR017 Risks related to Outpatient Setting Timely delivery of medications for the treatment of side effects of CAR-Ts in an outpatient setting Capacity building for outpatient CAR-T therapy involves the training of hospital nurses, medical assistants and consultancy service

JCAR017-Terms of cost structures amidst COVID-19Could be redefined in the form of bundled payment

Submit your Request for Proposals at bd@mellalta.com
https://mellalta.com/bristols-dlbcl-car-t-therapy-lisocabtagene-maraleucel-jcar017-future-strategy-latest-events/
End
Email:***@mellalta.com Email Verified
Tags:liso-cel and JCAR017
Industry:Health
Location:New York City - New York - United States
Subject:Partnerships
Account Email Address Verified     Account Phone Number Verified     Disclaimer     Report Abuse
Mellalta Meets PRs
Trending News
Most Viewed
Top Daily News



Like PRLog?
9K2K1K
Click to Share